

(This is only an advertisement for information purpose and not a prospectus announcement)



SAROJA PHARMA INDUSTRIES INDIA LIMITED

The Corporate Identification Number of our Company is U24110MH2019PLC319508

Our Company was originally incorporated as "Saroja Pharma Industries India Private Limited" on 14th January, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai Maharashtra. Later on, company was converted into public limited company, the name of our Company has changed to "Saroja Pharma Industries India Limited" and fresh Certificate of Incorporation dated 18th April, 2023 has been issued by the Registrar of Companies, Mumbai Maharashtra. Corporate Identification Number of our Company is U24110MH2019PLC319508.

Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, Mumbai City, MAHARASHTRA - 400080
Corporate Office: Shop No. 209, 2nd Floor, Ecstasy, City of Joy, Jata Shankar Dosa Marg, Mulund West, Mumbai, MAHARASHTRA - 400080
Website: www.sarojapharma.com | **E-Mail:** info@sarojapharma.com | **Telephone:** +91 (022) 2081 0011
Company Secretary and Compliance Officer: Ms. Nikita Kumar

PROMOTER'S OF OUR COMPANY: MR. BIJU GOPINATHAN NAIR AND MR. MANISH DASHARATH KAMBLE

THE ISSUE

PUBLIC ISSUE OF UPTO 10,84,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF SAROJA PHARMA INDUSTRIES INDIA LIMITED ("SAROJA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 911.23 LAKHS (THE "ISSUE"), OUT OF WHICH 54,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 84/- EACH AGGREGATING TO ₹ 45.69 LAKHS WILL BE RESERVED FOR MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 10,30,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE AGGREGATING TO ₹ 865.54 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.98% AND 25.63% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THIS ISSUE IS BEING IN TERMS OF CHAPTER IX OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED FROM TIME TO TIME.

For Further details see "TERMS OF THE ISSUE" beginning on page no. 195 of the Prospectus.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS ₹ 84/-
 THE ISSUE PRICE IS 8.4 TIMES OF THE FACE VALUE**

ISSUE

**OPENS ON: THURSDAY, 31ST AUGUST, 2023
 CLOSED ON: TUESDAY, 05TH SEPTEMBER, 2023**

MINIMUM LOT SIZE

**1,600 EQUITY SHARES FOR RETAIL INDIVIDUAL INVESTORS
 3,200 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER FOR HNI/QIB CATEGORY**

ASBA*

Simple, Safe, Smart way to application - Make use of it. *Application Supported by blocked amount (ASBA) is better way of applying to issue by simple blocking the fund in the bank account, investor can avail the same. For details, check section on ASBA below.

UPI NOW AVAILABLE IN ASBA FOR RETAIL INDIVIDUAL INVESTORS



For Details on the ASBA and UPI process, please refer to the details given in ASBA form and Abridge Prospectus and please refer to the section "ISSUE PROCEDURE" beginning on page no. 203 of the Prospectus.
 The process is also available on the website of National Stock Exchange of India Limited (www.nseindia.com), in General Information Document.
 List of Banks Supporting UPI is also available on the website of SEBI (www.sebi.gov.in).

IN TERMS OF THE SEBI CIRCULAR BEARING NUMBER: CIR/CFD/POLICYCELL/11/2015, DATED NOVEMBER 10, 2015 AND THE ALL-POTENTIAL INVESTORS SHALL PARTICIPATE IN THE ISSUE ONLY THROUGH AN ASBA FACILITY, PROCESS PROVIDING DETAILS ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS ('SCSBS') FOR THE SAME. FURTHER PURSUANT TO SEBI CIRCULAR BEARING NO. SEBI/HO/CFD/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019. FOR IMPLEMENTATION OF PHASE II FOR UPI FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019, ALL POTENTIAL BIDDERS (EXCEPT ANCHOR INVESTORS) ARE REQUIRED TO MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") PROCESS PROVIDING DETAILS OF THEIR RESPECTIVE ASBA ACCOUNTS OR UPI ID (IN CASE OF RIIS), IN WHICH THE CORRESPONDING APPLICATION AMOUNTS WILL BE BLOCKED BY THE SCSBS OR UNDER THE UPI MECHANISM, AS APPLICABLE. FOR DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO "ISSUE PROCEDURE" ON PAGE NO. 203 OF THE PROSPECTUS, IN CASE OF DELAY, IF ANY IN UNBLOCKING/REFUND OF THE FUND, OUR COMPANY SHALL PAY INTEREST ON THE APPLICATION MONEY AT THE RATE OF 15% PER ANNUM FOR THE PERIOD OF DELAY.

Information As Required Under Section 30 Of The Companies Act, 2013:

The information regarding the content of Memorandum of Association of our Company as regards Main Objects are available in the prospectus of the Company on page no. 119 of the Prospectus. The Liability of the members is limited. Our Authorized share capital comprises of 50,00,000 Equity Shares of ₹ 10/- each aggregating to ₹ 500 Lakh. The present issued, subscribed and paid-up share capital comprises of 29,35,686 Equity Shares of ₹ 10/- each aggregating to ₹ 293.57 Lakh. We are proposing to issue 10,84,800 Equity Shares of ₹ 10/- each in terms of the Prospectus dated 25th August, 2023 at a price of ₹ 84/- per shares including premium of ₹ 74/- per equity shares. The Names of signatories to the Memorandum of Association of our Company at the time of incorporation and number of shares subscribed by them is as follow:

| S. No. | Name of Signatories | No. of Equity Shares subscribed (Face Value ₹10/- each) |
|--------|-----------------------------|---|
| 1. | Mr. Biju Gopinathan Nair | 7,000 |
| 2. | Mr. Manish Dasharath Kamble | 3,000 |
| | Total | 10,000 |

The Present Capital structure of the Company is as follow:

| S. No. | Category of Shareholders | No. of Shareholders | No. of Share held | % |
|--------|------------------------------|---------------------|-------------------|---------------|
| 1. | Promoters and Promoter Group | 9 | 29,35,686 | 100.00 |
| 2. | Public | 0 | 0 | 0.00 |
| | Total | 9 | 29,35,686 | 100.00 |

PROPOSED LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time, Our Company has received in-principle approval letter dated 10th August, 2023 from National Stock Exchange of India Limited ("NSE") for using its name in this offer documents for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this issue, the Designated Stock Exchange will be the NSE.

DISCLAIMER CLAUSE OF SEBI

Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulation, 2018, the Drafted Offer Document had not been filed with SEBI. However SEBI shall not issue any observation on the Draft Prospectus / Prospectus. Hence there is no such specified disclaimer clause of SEBI. However investors may refer full text of the "DISCLAIMER CLAUSE OF SEBI" beginning on page no. 186 of the Prospectus.

DISCLAIMER CLAUSE OF NSE

"It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Prospectus has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the "DISCLAIMER CLAUSE OF NSE" appearing on page no. 186 of the Prospectus".

LEAD MANAGER TO THE ISSUE



SWASTIKA INVESTMART LIMITED;
SEBI Reg. Number: INM000012102;
Address: Flat No.18, 2nd Floor, North Wing, Madhaveshwar Co-op- Hsg Society Ltd, Madhav Nagar, 11/12, S. V. Road, Andheri W, Mumbai- 400058;
Tel No.: +91- 22-26254568-69;
Fax No.: +91-731-664 4300;
Email Id: merchantbanking@swastika.co.in;
Investors Grievance Id: mb.investorgrievance@swastika.co.in;
Website: www.swastika.co.in;
Contact Person: CS Mohit R. Goyal;
CIN: L65910MH1992PLC067052.

REGISTRAR TO THE ISSUE



KFIN TECHNOLOGIES LIMITED;
SEBI Registration No: INR000000221;
Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 032, Telangana;
Telephone Number: +91 40 6716 2222;
Toll Free Number: 1800 309 4001;
Email: spii.ipo@kfintech.com;
Investors Grievance Id: einward.ris@kfintech.com;
Website: www.kfintech.com;
Contact Person: Mr. M Murali Krishna;
CIN: L72400TG2017PLC117649

COMPLIANCE OFFICER



SAROJA PHARMA INDUSTRIES INDIA LIMITED
Address: Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, NA Mumbai City MH 400080 IN
Tel No.:- +91 (022) 2081 0011;
Website: www.sarojapharma.com;
Contact Person: Ms. Nikita Kumar;
E-Mail: info@sarojapharma.com/
 cs@sarojapharma.com;
CIN: U24110MH2019PLC319508
 Investors can contact the company secretary and compliance officer or the LM or the Registrar to the Issue in case of any pre-issue related problems, such as non-receipt of letter of offer, non-credit of allotted equity shares in the respective beneficiary account and refund orders etc.

CREDIT RATING: As this is an issue of Equity Shares there is no credit rating for this issue.

DEBENTURE TRUSTEES: As this is an issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, there is no requirement of appointing an IPO Grading agency.

BASIS OF ISSUE PRICE: The Issue Price is determined by Company in consultation with the Lead Manager. The financial data presented in Section titled "BASIS FOR ISSUE PRICE" on page no. 74 of the Prospectus are based on Company's Restated Financial Statements. Investors should also refer to the Section/Chapter titled "RISK FACTORS" and "RESTATE FINANCIAL STATEMENT" on page No. 18 and 139 respectively of the Prospectus to get more informed view before making the investment decision.

RISK TO INVESTORS: Investment in equity and equity-related securities involve a degree of risk and investors should not invest any fund in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risk involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the Section titled "RISK FACTOR" beginning on page no. 18 of the Prospectus.

AVAILABILITY OF APPLICATION FORMS: Application forms can be obtained from the Company i.e. Saroja Pharma Industries India Limited, the Lead Manager to the issue i.e. Swastika Investmart Limited, the Registrar to the issue i.e. Kfin Technologies Limited. The application forms shall also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. Application supported by Block Amount forms shall be available with designated branches of Self Certified Syndicate Banks, the list of which is available at website of the Stock Exchange and SEBI.

AVAILABILITY OF PROSPECTUS: Investor are advised to refer to the Prospectus, and the Risk Factor Contained therein, before applying in the issue. Full copy of the Prospectus is available at the website of SEBI at (www.sebi.gov.in); website of Stock Exchange at (www.nseindia.com), the website of Lead Manager at (www.swastika.co.in); and website of the company at (www.sarojapharma.com). Investor should note that investment in equity shares involves high degree of risk. For details, investor should refer to and rely on the Prospectus, including the section titled "RISK FACTOR" on page no. 18 of the Prospectus, which has been filed with ROC.

APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors may apply through ASBA. ASBA can be availed by all the investors except Anchor Investors. All potential investors are mandatorily required to participate in the issue through an Application Supported by Blocked Amount ("ASBA") process. The investors are required to fill the ASBA forms and submit the same to their Banks which, in return will block the amount in the account as per the authority contained in ASBA form and shares. Hence, there will be no need of refund. The ASBA application forms can also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. For more details on the ASBA process, please refer to the details given in application forms and abridged prospectus and also please refer to the Section "ISSUE PROCEDURE" on page no. 203 of the Prospectus.

Capitalized terms used herein and not specifically defined herein shall have the meaning given to such terms in the Prospectus.

BANKER TO THE ISSUE AND SPONSER BANK: AXIS BANK LIMITED

SEBI Reg. No.: INBI00000017;
Address: CTS No. 3203, Old Suchak Niwas Murbad Road, Bhiwandi - 421301;
Tel. No.: +91-9167105741, **Email:** kalyanwest.branchhead@axisbank.com, **Website:** www.axisbank.com;
Contact Person: Mr. Anil Kanekar

Place : Mumbai
Date : 29th August, 2023

SAROJA PHARMA INDUSTRIES INDIA LIMITED is proposing, subject to market conditions and other considerations, a public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Mumbai ("ROC"). The Prospectus is available on the website of the SEBI at (www.sebi.gov.in), the website of the Lead Manager at (www.swastika.co.in) and website of Company at (www.sarojapharma.com) and on the website of National Stock Exchange of India Limited at (www.nseindia.com). Investor should note that investment in equity shares involved high degree of risk. For details, investors should refer to and reply on the Prospectus, including the section titled "RISK FACTORS" on page no. 18 of the Prospectus, which has been filed with ROC, before making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 as amended ("The Security Act") and may not be issued or sold within the United States (as defined in regulations under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirement of the Securities Act. The equity shares are being offered and sold only outside the United States in offshore transaction in compliance with regulations under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occurs.

On behalf of the Board of Directors
For, Saroja Pharma Industries India Limited
 Sd/-
Mr. Biju Gopinathan Nair
 Chairman and Managing Director
 DIN: 08330223

(This is only an advertisement for information purpose and not a prospectus announcement)

Saroja Pharma Industries
India Ltd.

SAROJA PHARMA INDUSTRIES INDIA LIMITED

The Corporate Identification Number of our Company is U24110MH2019PLC319508

Our Company was originally incorporated as "Saroja Pharma Industries India Private Limited" on 14th January, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai Maharashtra. Later on, company was converted into public limited company, the name of our Company has changed to "Saroja Pharma Industries India Limited" and fresh Certificate of Incorporation dated 18th April, 2023 has been issued by the Registrar of Companies, Mumbai Maharashtra. Corporate Identification Number of our Company is U24110MH2019PLC319508.

Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, Mumbai City, MAHARASHTRA - 400080
Corporate Office: Shop No. 209, 2nd Floor, Ecstasy, City of Joy, Jata Shankar Dosa Marg, Mulund West, Mumbai, MAHARASHTRA - 400080
Website: www.sarojapharma.com | **E-Mail:** info@sarojapharma.com | **Telephone:** +91 (022) 2081 0011
Company Secretary and Compliance Officer: Ms. Nikita Kumar

PROMOTER'S OF OUR COMPANY: MR. BIJU GOPINATHAN NAIR AND MR. MANISH DASHARATH KAMBLE

THE ISSUE

PUBLIC ISSUE OF UPTO 10,84,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF SAROJA PHARMA INDUSTRIES INDIA LIMITED ("SAROJA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 911.23 LAKHS ("THE ISSUE"), OUT OF WHICH 54,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 84/- EACH AGGREGATING TO ₹ 45.69 LAKHS WILL BE RESERVED FOR MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 10,30,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE AGGREGATING TO ₹ 865.54 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.98% AND 25.63% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THIS ISSUE IS BEING IN TERMS OF CHAPTER IX OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED FROM TIME TO TIME.

For Further details see "TERMS OF THE ISSUE" beginning on page no. 195 of the Prospectus.

**THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS ₹ 84/-
THE ISSUE PRICE IS 8.4 TIMES OF THE FACE VALUE**

ISSUE

OPENS ON: THURSDAY, 31ST AUGUST, 2023

CLOSED ON: TUESDAY, 05TH SEPTEMBER, 2023

MINIMUM LOT SIZE

1,600 EQUITY SHARES FOR RETAIL INDIVIDUAL INVESTORS

3,200 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER FOR HNI/QIB CATEGORY

ASBA*

Simple, Safe, Smart way to application - Make use of it.

***Application Supported by blocked amount (ASBA) is better way of applying to issue by simple blocking the fund in the bank account, investor can avail the same. For details, check section on ASBA below.**

UPI NOW AVAILABLE IN ASBA FOR RETAIL INDIVIDUAL INVESTORS



For Details on the ASBA and UPI process, please refer to the details given in ASBA form and Abridge Prospectus and please refer to the section "ISSUE PROCEDURE" beginning on page no. 203 of the Prospectus.

The process is also available on the website of National Stock Exchange of India Limited (www.nseindia.com), in General Information Document.

List of Banks Supporting UPI is also available on the website of SEBI (www.sebi.gov.in).

IN TERMS OF THE SEBI CIRCULAR BEARING NUMBER: CIR/CFD/POLICYCELL/11/2015, DATED NOVEMBER 10, 2015 AND THE ALL-POTENTIAL INVESTORS SHALL PARTICIPATE IN THE ISSUE ONLY THROUGH AN ASBA FACILITY, PROCESS PROVIDING DETAILS ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS ("SCSBS") FOR THE SAME. FURTHER PURSUANT TO SEBI CIRCULAR BEARING NO. SEBI/HO/CFD/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019. FOR IMPLEMENTATION OF PHASE II FOR UPI FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019, ALL POTENTIAL BIDDERS (EXCEPT ANCHOR INVESTORS) ARE REQUIRED TO MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") PROCESS PROVIDING DETAILS OF THEIR RESPECTIVE ASBA ACCOUNTS OR UPI ID (IN CASE OF RIIS), IN WHICH THE CORRESPONDING APPLICATION AMOUNTS WILL BE BLOCKED BY THE SCSBS OR UNDER THE UPI MECHANISM, AS APPLICABLE. FOR DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO "ISSUE PROCEDURE" ON PAGE NO. 203 OF THE PROSPECTUS, IN CASE OF DELAY, IF ANY IN UNBLOCKING/REFUND OF THE FUND, OUR COMPANY SHALL PAY INTEREST ON THE APPLICATION MONEY AT THE RATE OF 15% PER ANNUM FOR THE PERIOD OF DELAY.

Information As Required Under Section 30 Of The Companies Act, 2013:

The information regarding the content of Memorandum of Association of our Company as regards Main Objects are available in the prospectus of the Company on page no. 119 of the Prospectus. The Liability of the members is limited. Our Authorized share capital comprises of 50,00,000 Equity Shares of ₹ 10/- each aggregating to ₹ 500 Lakh. The present issued, subscribed and paid-up share capital comprises of 29,35,686 Equity Shares of ₹ 10/- each aggregating to ₹ 293.57 Lakh. We are proposing to issue 10,84,800 Equity Shares of ₹ 10/- each in terms of the Prospectus dated 25th August, 2023 at a price of ₹ 84/- per shares including premium of ₹ 74/- per equity shares. The Names of signatories to the Memorandum of Association of our Company at the time of incorporation and number of shares subscribed by them is as follow:

| S. No. | Name of Signatories | No. of Equity Shares subscribed (Face Value ₹10/- each) |
|--------|-----------------------------|---|
| 1. | Mr. Biju Gopinathan Nair | 7,000 |
| 2. | Mr. Manish Dasharath Kamble | 3,000 |
| | Total | 10,000 |

The Present Capital structure of the Company is as follow:

| S. No. | Category of Shareholders | No. of Shareholders | No. of Share held | % |
|--------|------------------------------|---------------------|-------------------|---------------|
| 1. | Promoters and Promoter Group | 9 | 29,35,686 | 100.00 |
| 2. | Public | 0 | 0 | 0.00 |
| | Total | 9 | 29,35,686 | 100.00 |

PROPOSED LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time, Our Company has received in-principle approval letter dated 10th August, 2023 from National Stock Exchange of India Limited ("NSE") for using its name in this offer documents for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this issue, the Designated Stock Exchange will be the NSE.

DISCLAIMER CLAUSE OF SEBI

Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulation, 2018, the Drafted Offer Document had not been filed with SEBI. However SEBI shall not issue any observation on the Draft Prospectus / Prospectus. Hence there is no such specified disclaimer clause of SEBI. However investors may refer full text of the "DISCLAIMER CLAUSE OF SEBI" beginning on page no. 186 of the Prospectus.

DISCLAIMER CLAUSE OF NSE

"It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Prospectus has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the "DISCLAIMER CLAUSE OF NSE" appearing on page no. 186 of the Prospectus".

LEAD MANAGER TO THE ISSUE



SWASTIKA INVESTMART LIMITED;
SEBI Reg. Number: INM000012102;
Address: Flat No.18, 2nd Floor, North Wing, Madhaveshwar Co-op- Hsq Society Ltd, Madhav Nagar, 11/12, S. V. Road, Andheri W, Mumbai- 400058;
Tel No.: +91- 22-26254568-69;
Fax No.: +91-731-664 4300;
Email Id: merchantbanking@swastika.co.in;
Investors Grievance Id: mb.investorgrievance@swastika.co.in;
Website: www.swastika.co.in;
Contact Person: CS Mohit R. Goyal;
CIN: L65910MH1992PLC067052.

REGISTRAR TO THE ISSUE



KFIN TECHNOLOGIES LIMITED;
SEBI Registration No: INR00000221;
Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana;
Telephone Number: +91 40 6716 2222;
Toll Free Number: 1800 309 4001;
Email: spii.ipo@kfintech.com;
Investors Grievance Id: einward.ris@kfintech.com;
Website: www.kfintech.com;
Contact Person: Mr. M Murali Krishna;
CIN: L72400TG2017PLC117649

COMPLIANCE OFFICER



SAROJA PHARMA INDUSTRIES INDIA LIMITED
Address: Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, NA Mumbai City MH 400080 IN
Tel No.: +91 (022) 2081 0011;
Website: www.sarojapharma.com;
Contact Person: Ms. Nikita Kumar;
E-Mail: info@sarojapharma.com/
 cs@sarojapharma.com;
CIN: U24110MH2019PLC319508
 Investors can contact the company secretary and compliance officer or the LM or the Registrar to the Issue in case of any pre-issue related problems, such as non-receipt of letter of offer, non-credit of allotted equity shares in the respective beneficiary account and refund orders etc.

CREDIT RATING: As this is an issue of Equity Shares there is no credit rating for this issue.

DEBENTURE TRUSTEES: As this is an issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, there is no requirement of appointing an IPO Grading agency.

BASIS OF ISSUE PRICE: The issue Price is determined by Company in consultation with the Lead Manager. The financial data presented in Section titled "BASIS FOR ISSUE PRICE" on page no. 74 of the Prospectus are based on Company's Restated Financial Statements. Investors should also refer to the Section/Chapter titled "RISK FACTORS" and "RESTATED FINANCIAL STATEMENT" on page No. 18 and 139 respectively of the Prospectus to get more informed view before making the investment decision.

RISK TO INVESTORS: Investment in equity and equity-related securities involve a degree of risk and investors should not invest any fund in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risk involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the Section titled "RISK FACTOR" beginning on page no. 18 of the Prospectus.

AVAILABILITY OF APPLICATION FORMS: Application forms can be obtained from the Company i.e. Saroja Pharma Industries India Limited, the Lead Manager to the issue i.e. Swastika Investmart Limited, the Registrar to the issue i.e. Kfin Technologies Limited. The application forms shall also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. Application supported by Block Amount forms shall be available with designated branches of Self Certified Syndicate Banks, the list of which is available at website of the Stock Exchange and SEBI.

AVAILABILITY OF PROSPECTUS: Investor are advised to refer to the Prospectus, and the Risk Factor Contained therein, before applying in the issue. Full copy of the Prospectus is available at the website of SEBI at (www.sebi.gov.in); website of Stock Exchange at (www.nseindia.com), the website of Lead Manager at (www.swastika.co.in); and website of the company at (www.sarojapharma.com). Investor should note that investment in equity shares involves high degree of risk. For details, investor should refer to and rely on the Prospectus, including the section titled "RISK FACTOR" on page no. 18 of the Prospectus, which has been filed with ROC.

APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors may apply through ASBA. ASBA can be availed by all the investors except Anchor Investors. All potential investors are mandatorily required to participate in the issue through an Application Supported by Blocked Amount ("ASBA") process. The investors are required to fill the ASBA forms and submit the same to their Banks which, in return will block the amount in the account as per the authority contained in ASBA form and shares. Hence, there will be no need of refund. The ASBA application forms can also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. For more details on the ASBA process, please refer to the details given in application forms and abridged prospectus and also please refer to the Section "ISSUE PROCEDURE" on page no. 203 of the Prospectus.

Capitalized terms used herein and not specifically defined herein shall have the meaning given to such terms in the Prospectus.

BANKER TO THE ISSUE AND SPONSER BANK: AXIS BANK LIMITED

SEBI Reg. No.: INBI00000017;
Address: CTS No. 3203, Old Suchak Niwas Murbad Road, Bhiwandi - 421301;
Tel. No.: +91-9167105741. **Email:** kalyanwest.branchhead@axisbank.com, **Website:** www.axisbank.com;
Contact Person: Mr. Anil Kanekar

Place : Mumbai
Date : 29th August, 2023

SAROJA PHARMA INDUSTRIES INDIA LIMITED is proposing, subject to market conditions and other considerations, a public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Mumbai ("ROC"). The Prospectus is available on the website of the SEBI at (www.sebi.gov.in), the website of the Lead Manager at (www.swastika.co.in) and website of Company at (www.sarojapharma.com) and on the website of National Stock Exchange of India Limited at (www.nseindia.com). Investor should note that investment in equity shares involved high degree of risk. For details, investors should refer to and reply on the Prospectus, including the section titled "RISK FACTORS" on page no. 18 of the Prospectus, which has been filed with ROC, before making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 as amended ("The Security Act") and may not be issued or sold within the United States (as defined in regulations under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirement of the Securities Act. The equity shares are being offered and sold only outside the United States in offshore transaction in compliance with regulations under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occurs.

On behalf of the Board of Directors
For, Saroja Pharma Industries India Limited
 Sd/-
Mr. Biju Gopinathan Nair
 Chairman and Managing Director
 DIN: 08330223

(This is only an advertisement for information purpose and not a prospectus announcement)



SAROJA PHARMA INDUSTRIES INDIA LIMITED

The Corporate Identification Number of our Company is U24110MH2019PLC319508

Our Company was originally incorporated as "Saroja Pharma Industries India Private Limited" on 14th January, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, company was converted into public limited company, the name of our Company has changed to "Saroja Pharma Industries India Limited" and fresh Certificate of Incorporation dated 18th April, 2023 has been issued by the Registrar of Companies, Mumbai Maharashtra. Corporate Identification Number of our Company is U24110MH2019PLC319508.

Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, Mumbai City, MAHARASHTRA - 400080
Corporate Office: Shop No. 209, 2nd Floor, Ecstasy, City of Joy, Jata Shankar Dosa Marg, Mulund West, Mumbai, MAHARASHTRA - 400080
Website: www.sarojapharma.com | **E-Mail:** info@sarojapharma.com | **Telephone:** +91 (022) 2081 0011
Company Secretary and Compliance Officer: Ms. Nikita Kumar

PROMOTER'S OF OUR COMPANY: MR. BIJU GOPINATHAN NAIR AND MR. MANISH DASHARATH KAMBLE

THE ISSUE

PUBLIC ISSUE OF UPTO 10,84,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF SAROJA PHARMA INDUSTRIES INDIA LIMITED ("SAROJA" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 911.23 LAKHS ("THE ISSUE"), OUT OF WHICH 54,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 84/- EACH AGGREGATING TO ₹ 45.69 LAKHS WILL BE RESERVED FOR MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF 10,30,400 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 84/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 74/- PER EQUITY SHARE AGGREGATING TO ₹ 865.54 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.98% AND 25.63% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THIS ISSUE IS BEING IN TERMS OF CHAPTER IX OF THE SEBI (ICDR) REGULATIONS, 2018 AS AMENDED FROM TIME TO TIME.
For Further details see "TERMS OF THE ISSUE" beginning on page no. 195 of the Prospectus.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS ₹ 84/-
THE ISSUE PRICE IS 8.4 TIMES OF THE FACE VALUE

ISSUE

OPENS ON: THURSDAY, 31st AUGUST, 2023
CLOSED ON: TUESDAY, 05th SEPTEMBER, 2023

MINIMUM LOT SIZE

1,600 EQUITY SHARES FOR RETAIL INDIVIDUAL INVESTORS
3,200 EQUITY SHARES AND IN MULTIPLES OF 1,600 EQUITY SHARES THEREAFTER FOR HNI/QIB CATEGORY

ASBA*

Simple, Safe, Smart way to application - Make use of it. *Application Supported by blocked amount (ASBA) is better way of applying to issue by simple blocking the fund in the bank account, investor can avail the same. For details, check section on ASBA below.



UPI NOW AVAILABLE IN ASBA FOR RETAIL INDIVIDUAL INVESTORS

For Details on the ASBA and UPI process, please refer to the details given in ASBA form and Abridge Prospectus and please refer to the section "ISSUE PROCEDURE" beginning on page no. 203 of the Prospectus.
 The process is also available on the website of National Stock Exchange of India Limited (www.nseindia.com), in General Information Document.
 List of Banks Supporting UPI is also available on the website of SEBI (www.sebi.gov.in).

IN TERMS OF THE SEBI CIRCULAR BEARING NUMBER: CIR/CFD/POLICYCELL/11/2015, DATED NOVEMBER 10, 2015 AND THE ALL-POTENTIAL INVESTORS SHALL PARTICIPATE IN THE ISSUE ONLY THROUGH AN ASBA FACILITY. PROCESS PROVIDING DETAILS ABOUT THE BANK ACCOUNT WHICH WILL BE BLOCKED BY THE SELF-CERTIFIED SYNDICATE BANKS ("SCSBS") FOR THE SAME. FURTHER PURSUANT TO SEBI CIRCULAR BEARING NO. SEBI/HO/CFD/DIL2/CIR/P/2019/76 DATED JUNE 28, 2019. FOR IMPLEMENTATION OF PHASE II FOR UPI FACILITY, WHICH IS EFFECTIVE FROM JULY 01, 2019, ALL POTENTIAL BIDDERS (EXCEPT ANCHOR INVESTORS) ARE REQUIRED TO MANDATORILY UTILIZE THE APPLICATION SUPPORTED BY BLOCKED AMOUNT ("ASBA") PROCESS PROVIDING DETAILS OF THEIR RESPECTIVE ASBA ACCOUNTS OR UPI ID (IN CASE OF RIIS), IN WHICH THE CORRESPONDING APPLICATION AMOUNTS WILL BE BLOCKED BY THE SCSBS OR UNDER THE UPI MECHANISM, AS APPLICABLE. FOR DETAILS IN THIS REGARD, SPECIFIC ATTENTION IS INVITED TO "ISSUE PROCEDURE" ON PAGE NO. 203 OF THE PROSPECTUS, IN CASE OF DELAY, IF ANY IN UNBLOCKING/REFUND OF THE FUND, OUR COMPANY SHALL PAY INTEREST ON THE APPLICATION MONEY AT THE RATE OF 15% PER ANNUM FOR THE PERIOD OF DELAY.

Information As Required Under Section 30 Of The Companies Act, 2013:

The information regarding the content of Memorandum of Association of our Company as regards Main Objects are available in the prospectus of the Company on page no. 119 of the Prospectus. The Liability of the members is limited. Our Authorized share capital comprises of 50,00,000 Equity Shares of ₹ 10/- each aggregating to ₹ 500 Lakh. The present issued, subscribed and paid-up share capital comprises of 29,35,686 Equity Shares of ₹ 10/- each aggregating to ₹ 293.57 Lakh. We are proposing to issue 10,84,800 Equity Shares of ₹ 10/- each in terms of the Prospectus dated 25th August, 2023 at a price of ₹ 84/- per shares including premium of ₹ 74/- per equity shares. The Names of signatories to the Memorandum of Association of our Company at the time of incorporation and number of shares subscribed by them is as follow:

| S. No. | Name of Signatories | No. of Equity Shares subscribed (Face Value ₹10/- each) |
|--------|-----------------------------|---|
| 1. | Mr. Biju Gopinathan Nair | 7,000 |
| 2. | Mr. Manish Dasharath Kamble | 3,000 |
| | Total | 10,000 |

The Present Capital structure of the Company is as follow:

| S. No. | Category of Shareholders | No. of Shareholders | No. of Share held | % |
|--------|------------------------------|---------------------|-------------------|---------------|
| 1. | Promoters and Promoter Group | 9 | 29,35,686 | 100.00 |
| 2. | Public | 0 | 0 | 0.00 |
| | Total | 9 | 29,35,686 | 100.00 |

PROPOSED LISTING

The Equity Shares offered through the Prospectus are proposed to be listed on the EMERGE Platform of National Stock Exchange of India Limited ("NSE EMERGE"). In terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time, Our Company has received in-principle approval letter dated 10th August, 2023 from National Stock Exchange of India Limited ("NSE") for using its name in this offer documents for listing of our shares on the EMERGE Platform of National Stock Exchange of India Limited. For the purpose of this issue, the Designated Stock Exchange will be the NSE.

DISCLAIMER CLAUSE OF SEBI

Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulation, 2018, the Drafted Offer Document had not been filed with SEBI. However SEBI shall not issue any observation on the Draft Prospectus / Prospectus. Hence there is no such specified disclaimer clause of SEBI. However investors may refer full text of the "DISCLAIMER CLAUSE OF SEBI" beginning on page no. 186 of the Prospectus.

DISCLAIMER CLAUSE OF NSE

"It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Prospectus has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Prospectus. The investors are advised to refer to the Prospectus for the full text of the "DISCLAIMER CLAUSE OF NSE" appearing on page no. 186 of the Prospectus".

| LEAD MANAGER TO THE ISSUE | REGISTRAR TO THE ISSUE | COMPLIANCE OFFICER |
|---|---|---|
| <p>SWASTIKA INVESTMART LIMITED; SEBI Reg. Number: INM000012102; Address: Flat No.18, 2nd Floor, North Wing, Madhaveshwar Co-op- Hsg Society Ltd, Madhav Nagar, 11/12, S. V. Road, Andheri W, Mumbai- 400058; Tel No.: +91- 22-26254568-69; Fax No.: +91-731-664 4300; Email Id: merchantbanking@swastika.co.in; Investors Grievance Id: mb.investorgrievance@swastika.co.in; Website: www.swastika.co.in; Contact Person: CS Mohit R. Goyal; CIN: L65910MH1992PLC067052.</p> | <p>KFIN TECHNOLOGIES LIMITED; SEBI Registration No: INR000000221; Address: Selenium Tower-B, Plot 31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad-500 032, Telangana; Telephone Number: +91 40 6716 2222; Toll Free Number: 1800 309 4001; Email: spii.ipo@kfintech.com; Investors Grievance Id: einward.ris@kfintech.com; Website: www.kfintech.com; Contact Person: Mr. M Murali Krishna; CIN: L72400TG2017PLC117649</p> | <p>SAROJA PHARMA INDUSTRIES INDIA LIMITED Address: Registered office: 305, Kailash Tower, Shiv Shristi Complex, Goregaon Link Road, Mulund West, NA Mumbai City MH 400080 IN Tel No.: +91 (022) 2081 0011; Website: www.sarojapharma.com; Contact Person: Ms. Nikita Kumar; E-Mail: info@sarojapharma.com/ cs@sarojapharma.com; CIN: U24110MH2019PLC319508 <small>Investors can contact the company secretary and compliance officer or the LM or the Registrar to the Issue in case of any pre-issue related problems, such as non-receipt of letter of offer, non-credit of allotted equity shares in the respective beneficiary account and refund orders etc.</small></p> |

CREDIT RATING: As this is an issue of Equity Shares there is no credit rating for this issue.

DEBENTURE TRUSTEES: As this is an issue of Equity Shares, the appointment of Trustees is not required.

IPO GRADING: Since the issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, there is no requirement of appointing an IPO Grading agency.

BASIS OF ISSUE PRICE: The issue Price is determined by Company in consultation with the Lead Manager. The financial data presented in Section titled "BASIS FOR ISSUE PRICE" on page no. 74 of the Prospectus are based on Company's Restated Financial Statements. Investors should also refer to the Section/Chapter titled "RISK FACTORS" and "RESTATED FINANCIAL STATEMENT" on page No. 18 and 139 respectively of the Prospectus to get more informed view before making the investment decision.

RISK TO INVESTORS: Investment in equity and equity-related securities involve a degree of risk and investors should not invest any fund in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this offering. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risk involved. The Equity Shares offered in the Issue have neither been recommended nor approved by Securities and Exchange Board of India nor does Securities and Exchange Board of India guarantee the accuracy or adequacy of the Prospectus. Specific attention of the investors is invited to the Section titled "RISK FACTOR" beginning on page no. 18 of the Prospectus.

AVAILABILITY OF APPLICATION FORMS: Application forms can be obtained from the Company i.e. Saroja Pharma Industries India Limited, the Lead Manager to the issue i.e. Swastika Investmart Limited, the Registrar to the issue i.e. Kfin Technologies Limited. The application forms shall also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. Application supported by Block Amount forms shall be available with designated branches of Self Certified Syndicate Banks, the list of which is available at website of the Stock Exchange and SEBI.

AVAILABILITY OF PROSPECTUS: Investor are advised to refer to the Prospectus, and the Risk Factor Contained therein, before applying in the issue. Full copy of the Prospectus is available at the website of SEBI at (www.sebi.gov.in); website of Stock Exchange at (www.nseindia.com), the website of Lead Manager at (www.swastika.co.in); and website of the company at (www.sarojapharma.com). Investor should note that investment in equity shares involves high degree of risk. For details, investor should refer to and rely on the Prospectus, including the section titled "RISK FACTOR" on page no. 18 of the Prospectus, which has been filed with ROC.

APPLICATION SUPPORTED BY BLOCKED AMOUNT (ASBA): Investors may apply through ASBA. ASBA can be availed by all the investors except Anchor Investors. All potential investors are mandatorily required to participate in the issue through an Application Supported by Blocked Amount ("ASBA") process. The investors are required to fill the ASBA forms and submit the same to their Banks which, in return will block the amount in the account as per the authority contained in ASBA form and shares. Hence, there will be no need of refund. The ASBA application forms can also be downloaded from the website of National Stock Exchange of India Limited i.e. www.nseindia.com. For more details on the ASBA process, please refer to the details given in application forms and abridged prospectus and also please refer to the Section "ISSUE PROCEDURE" on page no. 203 of the Prospectus.

Capitalized terms used herein and not specifically defined herein shall have the meaning given to such terms in the Prospectus.

BANKER TO THE ISSUE AND SPONSER BANK: AXIS BANK LIMITED

SEBI Reg. No.: INBI00000017;
Address: CTS No. 3203, Old Suchak Niwas Murbad Road, Bhiwandi - 421301;
Tel. No.: +91-9167105741, **Email:** kalyanwest.branchhead@axisbank.com, **Website:** www.axisbank.com;
Contact Person: Mr. Anil Kanekar

On behalf of the Board of Directors
For, Saroja Pharma Industries India Limited

Mr. Biju Gopinathan Nair
 Chairman and Managing Director
 DIN: 08330223

Place : Mumbai
Date : 29th August, 2023

SAROJA PHARMA INDUSTRIES INDIA LIMITED is proposing, subject to market conditions and other considerations, a public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Mumbai ("ROC"). The Prospectus is available on the website of the SEBI at (www.sebi.gov.in), the website of the Lead Manager at (www.swastika.co.in) and website of Company at (www.sarojapharma.com) and on the website of National Stock Exchange of India Limited at (www.nseindia.com). Investor should note that investment in equity shares involves high degree of risk. For details, investors should refer to and rely on the Prospectus, including the section titled "RISK FACTORS" on page no. 18 of the Prospectus, which has been filed with ROC, before making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933 as amended ("The Security Act") and may not be issued or sold within the United States (as defined in regulations under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirement of the Securities Act. The equity shares are being offered and sold only outside the United States in offshore transaction in compliance with regulations under the Securities Act and the applicable laws of the jurisdiction where those offers and sales occurs.